Cleo Diagnostics Ltd (ASX:COV)
Australia flag Australia · Delayed Price · Currency is AUD
0.525
+0.020 (3.96%)
Last updated: Mar 10, 2026, 11:21 AM AEST

Cleo Diagnostics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23
Other Revenue
2.560.850.21-
Revenue
2.560.850.21-
Revenue Growth (YoY)
1115.45%300.91%--
Gross Profit
2.560.850.21-
Selling, General & Admin
2.481.881.11.37
Research & Development
3.82.882.570.25
Other Operating Expenses
0.10.10.120.04
Operating Expenses
6.444.933.851.7
Operating Income
-3.87-4.08-3.64-1.7
Interest Expense
---0.03-0.11
Interest & Investment Income
0.240.340.39-
Other Non Operating Income (Expenses)
-0.4-0.26-0.480.08
Pretax Income
-4.03-4-3.76-1.73
Net Income
-4.03-4-3.76-1.73
Net Income to Common
-4.03-4-3.76-1.73
Shares Outstanding (Basic)
12912911726
Shares Outstanding (Diluted)
12912911726
Shares Change (YoY)
10.54%9.53%346.76%-
EPS (Basic)
-0.03-0.03-0.03-0.07
EPS (Diluted)
-0.03-0.03-0.03-0.07
Free Cash Flow
-2.52-2.91-2.03-0.72
Free Cash Flow Per Share
-0.02-0.02-0.02-0.03
Gross Margin
100.00%100.00%100.00%-
Operating Margin
-151.15%-483.01%-1727.45%-
Profit Margin
-157.36%-473.17%-1783.22%-
Free Cash Flow Margin
-98.35%-344.57%-964.47%-
EBITDA
-3.81-4.02-3.58-1.66
D&A For EBITDA
0.060.060.060.04
EBIT
-3.87-4.08-3.64-1.7
Source: S&P Capital IQ. Standard template. Financial Sources.